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ABSTRACT 
Extracorporeal Membrane Oxygenation (ECMO) therapy is a growing and developing 
therapy in critical care medicine for patients that are in severe cardiovascular and/or pulmonary 
failure. This patient population is very complex, including complex coagulopathies. These 
coagulopathies are related to both the underlying cause and to the ECMO circuit itself. Current 
knowledge and available tools are quickly evolving while clinicians and researchers look for 
better ways to understand and treat this patient population. This rapidly changing care 
environment has not provided any standardized education for registered nurses (RNs) that are 
caring for these patients at the bedside. This DNP project attempts to close this gap in knowledge 
and provide digestible information for RNs to better the care that they provide to the ECMO 
patients in regard to coagulopathies. An education module based on the most current research 
and common practices was developed and shared with clinicians with a variety of backgrounds 
that care for ECMO patients. Their expert opinions were elicited to evaluate and provide the 
necessary feedback to ensure that the education would achieve closing this gap of knowledge. 
Finally, this module will be disseminated through publication to share with the critical care 
community. 
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INTRODUCTION 
Extracorporeal membrane oxygenation (ECMO) is a therapy used in the intensive care 
units (ICU) as a life support therapy. This therapy provides the support to the lungs, heart, or 
both organs in critical illnesses, such as acute respiratory distress syndrome (ARDS) or a 
myocardial infarction (MI). This therapy affords the affected organs time to heal while on other 
medical supportive therapies to reverse the cause of the insult (American Thoracic Society, 
2016). ECMO is invasive as it requires a large catheter(s) that carry large amounts of blood 
outside of the body through an oxygenator and a pump that replaces oxygen, removes carbon 
dioxide (CO2), and pumps the blood back to the body (American Thoracic Society, 2016). The 
ECMO machine can filter and pump between three to eight liters per minute (American Thoracic 
Society, 2016). The machine must be closely monitored and managed by a trained nurse, 
respiratory therapist, or perfusionists, called an ECMO specialist (American Thoracic Society, 
2016). This therapy carries high risks of coagulopathy such as thrombosis and bleeding. The risk 
of thrombosis is treated with anticoagulants, and often, because of this treatment and other 
inflammatory reactions, bleeding occurs. Current research and common practice supports the use 
of activated partial thromboplastin time (aPTT) and activated clotting time (ACT) laboratory 
values to titrate anticoagulants to mitigate these risks (Bollinger, Zenklusen, & Tanaka, 2016). 
These tests measure very specific fragments of the clotting cascade, and do not provide an 
overall assessment of the individual patients clotting propensities (Bollinger, Zenklusen, & 
Tanaka, 2016). Because ECMO increases the complexity of coagulopathies, the suitability of 
these specific tests in this population may be brought into question (Bollinger, Zenklusen, & 
Tanaka, 2016). 
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Thromboelastography (TEG) testing is a laboratory method that provides a 
comprehensive assessment of complex coagulopathy. It has progressively been utilized in 
critically complex patients, particularly trauma patients (Da Luz et al., 2014). However, how this 
laboratory method can improve the management of coagulopathy complications in patients 
requiring ECMO therapy has yet to be explored in depth.  
Background Knowledge 
ECMO 
Several types of therapeutic application for ECMO are practiced. Venovenous (VV) is 
used to support hypoxic, hypercapnic, or mixed respiratory failure when mechanical ventilation 
is unable to support ventilation or as a bridge to lung transplantation (Conrad & Rycus, 2012). 
VV ECMO uses an oxygenator that acts as an artificial lung, allowing oxygen and carbon 
dioxide gas exchange (Makdisi & Wang, 2015). It is the fastest growing modality in adults, 
gaining momentum following the CESAR trial (Peek et al., 2009). Before this study, the use of 
ECMO in adults was thought to have little benefit based on previous RCT’s (Conrad & Rycus, 
2012). The development of a dual lumen cannula with percutaneous cannulation around this time 
also contributed to the safety of VV EMCO in adults (Conrad & Rycus, 2012).  
Venoarterial (VA) ECMO is used for cardiac failure that has not responded to other 
supportive measures, such as fluid resuscitation, inotropic agents, or an intra-aortic balloon- 
pump (Makdisi & Wang, 2015). This modality is also growing in usage, but survival rates 
remain consistently low around 44% (Conrad & Rycus, 2012). In VA ECMO, the cannulas are 
positioned in the vena cava to off load the work of the heart, and subsequently the rest of the 
heart. This allows time for the contractile function to return. The blood is returned to the aorta in 
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retrograde direction, which raises blood pressure and allows for end-organ and coronary 
perfusion (Thiagarajan, Yarlagadda, & Bratton, 2012).  
VAV ECMO is also used for patient’s that are in multiorgan system failure and require 
the support of both cardiac flow and respiratory support. This can be managed by adding or 
changing the insertion sites of the ECMO cannulas. Extracorporeal cardiopulmonary 
resuscitation (ECPR) is emergency cannulation for ECMO typically performed in the emergency 
room incorporated into cardiopulmonary resuscitation (CPR) with a percutaneous approach, but 
the mechanism of the therapy remains the same (Pappalardo & Montisci, 2017). Improved 
outcomes compared to conventional CPR have not been established and the efficacy is still being 
debated (Pappalardo & Montisci, 2017). For the purpose of this project, education will focus on 
VV and VA ECMO.  
Patients that are considered for ECMO are among the most critically ill. It is a last 
resource when other methods of life support have failed. The Murray Score can be used to 
determine the need of a referral to an ECMO center for respiratory failure when other methods 
have failed to properly oxygenate the patient. With increasing rates of utilization of ECMO, 
Extracorporeal Life Support Organization (ELSO) also recommends tools to help predict 
mortality of adult patients for VA or VV ECMO, including the Survival after Veno-Arterial 
ECMO (SAVE) score or the Respiratory ECMO Survival Prediction (RESP) score. These scores 
are based on the ELSO registry where ECMO centers internationally enter their data on patient 
outcomes and ECMO run details (Schmidt et al., 2014; Schimdt et al., 2015). These scores help 
clinicians to guide treatment in these critically ill patients based by stratifying risks and predicted 
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mortality, with the understanding that this tool is not to assess who goes on ECMO (Schmidt et 
al., 2015).  
ECMO and the pro-coagulant state. The use of ECMO as a supportive or rescue 
therapy for patients in acute severe cardiac failure, and/or severe respiratory failure has been well 
documented (Auborn et al., 2013). The most common complications related to ECMO are major 
bleeding, found in about 30% of this population, and thrombosis, found in 15% according to 
ELSO (Aubron et al., 2013). However, thrombosis is likely underdiagnosed (Aubron et al., 
2013). Thrombosis and major clot formation in the circuit can be fatal (Aubron et al., 2016). 
Because the development of thrombosis presents such a high mortality risk, intravenous 
anticoagulants are routinely used prophylactically (Aubron et al., 2016). Anticoagulation therapy 
can be conservative or aggressive depending on the needs of the patient and whether they require 
VV ECMO or VA ECMO (ELSO, 2014). As a result of anticoagulation therapy, increased 
bleeding can occur and then is managed by regularly reviewing laboratory values (e.g., aPTT, 
ACT, TEG) anticoagulation therapy is subsequently adjusted as needed (Aubron et al., 2016).  
To understand the complexity of the coagulopathy of an ECMO patient, health 
professionals need to understand the pathophysiology of these complex complications. There are 
several events that can increase the risk of thrombosis in this population. The illness the patient 
is experiencing can cause a systemic inflammatory response syndrome (SIRS) or disseminated 
intravascular coagulation (DIC), through either trauma, major surgery, massive blood 
transfusion, or sepsis (Samuels, Moore, & Moore, 2018). This causes activation of the clotting 
cascade that can result in increased formation of thrombin and subsequently, thrombosis and 
bleeding in the case of DIC (Samuels, Moore, & Moore, 2018). ECMO exposes the blood to a 
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non-endothelial artificial surface, which also can trigger an inflammatory response (Esper et al., 
2017).  
One of the body’s inflammatory response to exposure of blood to the ECMO circuit is 
hypercoagulopathy. In healthy individuals, fibrinolysis is the natural response of the clotting 
cascade to clot formation and subsequent breakdown in the production of plasmin and 
plasminogen activators. (Kolev & Longstaff, 2016). Hyperfibrinolysis (sometimes referred to as 
primary) occurs in a disease state such as liver cirrhosis where many clotting factors produced 
complicate the balance of such factors (Kolev & Longstaff, 2016). Secondary hyperfibrinolysis 
becomes a concern in ECMO patients, usually identified as an aspect of disseminated 
intravascular coagulation (DIC). DIC in ECMO patients is a process that lacks definitive 
identification in ECMO populations based on the scoring system criteria from the International 
Society on Thrombosis and Haemostasis (Bembea, 2016). This phenomenon is rare in ECMO 
but presents one of the more complex challenges in managing coagulation in patients.  
ECMO and anticoagulation management. The current use of anticoagulants to prevent 
thrombosis and manage bleeding requires further explanation to better understand how TEG 
might improve management in this population. Esper et al. (2017) looked at multiple academic 
institutions from North America, Europe, Australia, Asia, and South America to examine the 
differences in anticoagulant methods in their ECMO programs. Most programs used heparin, 
with only two using bivalirudin (Esper et al., 2017). Many of the programs used aPTT, ACT, or 
antithrombin III (AT) levels to guide anticoagulant protocols, with many inconsistencies and no 
agreed upon level of anticoagulation (Esper et al., 2017). About a third use TEG as an adjunct or 
primary guide to the use of anticoagulants (Esper et al., 2017)  
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TEG 
Thromboelastography is widely used in trauma, hepatobiliary, and cardiac surgeries to 
identify and predict post-operative bleeding and thrombosis (Hobson et al., 2006). The benefit of 
this test is that it is a whole blood test that measures a global hemostasis profile, including 
clotting times (R time), clot kinetics (K, α), clot strength (MA), and clot lysis (LY30) (Lequier, 
Annich, & Massicotte, 2012). The use of this test has the potential to better assess the needs of 
the patient on ECMO regarding these issues by looking at a complex and complete method to 
better target care (Haemonetics, n.d.). Isolated factors of coagulation, such as an ACT or aPTT, 
are common tests used in titrating anticoagulants in ECMO patients but are isolated factors of the 
clotting cascade (da Luz, Nascimento, & Rizoli, 2013). By providing a comprehensive depiction 
of the patient’s hemostasis, ECMO may better guide anticoagulation in addition to those isolated 
values (Hobson et al., 2006). 
ECMO as a rescue therapy has only been used and studied in the adult population for 
about 20 years (Fortenberry, 2012). The utilization of this therapy in adults remains relatively 
new in the medical world. This is also a population where TEG testing may be ideal for 
management of the two most common complications- thrombosis and bleeding. Anticoagulation 
medications, commonly heparin, have been used based on the ease and familiarity of this drug 
with providers (Lequier, Annich, & Massicotte, 2012). The use of a more comprehensive 
assessment of the coagulation status holds potential to decrease mortality and complications 
related to major bleeding or thrombotic complications. TEG also can identify dangerous 
coagulopathies, such as secondary fibrinolysis, which is otherwise difficult to identify (Kolev & 
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Longstaff, 2016). Education on better ways to interpret response to therapy is the first step to 
better outcomes.  
Local Problem 
In the intensive care units (ICU) at Banner University Medical Center in Phoenix 
(BUMCP), ECMO is the therapy of choice for severe decline in pulmonary or cardiac function. 
The ECMO team, including ECMO specialists, the ICU medical team, and the cardiothoracic 
surgery providers collaborate to manage the anticoagulation therapy for this population. There 
have been numerous cases of severe bleeding and thrombosed circuits that have resulted in 
increased complications, longer hospital stays, and high mortality rates. To mitigate these 
adverse events and better manage these patients, the ECMO team of providers are developing a 
protocol to titrate bivalirudin and heparin anticoagulation therapy based on both the aPTT and 
the TEG profile. Because there has been no formal education for nurses and residents regarding 
TEG and its application to managing an ECMO patient’s coagulation state, confusion and 
uncertainty exist in the team. This uncertainty may impact the success of a new protocol. The 
development of the protocol and the care of the patients will be better achieved through 
continuing education of the staff to facilitate best practice and safety for the ECMO patients 
regarding TEG application and anticoagulation. 
Purpose 
There is an identified need for more practitioners to understand the benefits of TEG 
testing in high risk patients of hemorrhage and thrombosis. ECMO patients are an ideal 
population to examine the benefits to increasing the education and use of TEG in healthcare 
professionals. The purpose of the proposed project is to develop a continuing education model on 
   
15 
the pathophysiology, interpretation, and practice implications of TEG use in patients on ECMO. 
The intent is not to make recommendations to anticoagulation protocols, but to better support the 
principles of ECMO, including the use of TEG, and anticoagulation strategies, to support 
patients. Further, the continuing education module may be useful for not only local nurses but 
may serve as a publishable continuing education module that would serve a wider population of 
nurses. This notion underpins the study question/aims of this project.  
For registered nurse ECMO specialists (P), is an educational module on the use of TEG 
in ECMO patients (I) useful with respect to providing knowledge of pathophysiology, 
interpretation, and practice applications related to understanding anticoagulation protocols (O)? 
The aims of this project are to 1) develop a continuing education module on TEG to inform 
anticoagulation therapies in ECMO; and, 2) solicit expert opinions of ECMO and TEG 
specialists regarding the usefulness of the continuing education module.  
Theoretical Framework 
The theoretical framework chosen to guide this project is the Stetler Model. The Stetler 
Model is a research utilization (RU) framework that provides a guide to incorporate research into 
evidence-based practice (EBP) (Stetler, 2001). This model is designed to be oriented towards 
practitioners to guide critical thinking and decision making in both a group setting and for the 
individual practitioner (Stetler, 2001). This framework encourages and highlights the importance 
of review and adjustments along the way (Romp & Kiehl, 2009). Stetler (2010) describes 
research to be developed in three different applications and apply it to this framework: 
instrumental, conceptual, and symbolic (NCCMT, 2001). Instrumental is the use of objective, 
factual knowledge, conceptual knowledge changes how a person sees and understands 
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knowledge, and the symbolic knowledge is the strategic ability to use scientific evidence to 
persuade or influence policy change or how others use and perceive the knowledge (Stetler, 
1994). This project is a continuing education module formatted to improve the knowledge of 
TEG and its interpretation regarding a patient’s coagulable state while on ECMO. By using a 
theoretical framework to develop an educational module that support decision-making skills, and 
incorporates different usage of data to persuade change, it facilitates evaluation for individuals 
and groups, and provides a model for evolving EBP over time (Stetler, 2001).  
The phases include preparation, validation, comparative evaluation, application, and 
evaluation (Romp & Kiehl, 2009). In the preparation phase, a need is identified, variations in 
practice is evaluated, and an end goal is identified (Stetler, 2010). Regarding this project, there is 
an identified need for education in understanding the role that TEG can provide in patients with 
varying coagulable states based on feedback of the ECMO specialists and the ECMO 
coordinator. Variation in different measures of assessing hypercoagulable states are inconsistent 
throughout different programs (REF). The second phase, validation, requires the finding, 
verifying, and investigating the current literature and research available (Stetler, 2010). We 
discussed the current literature and trends to manage anticoagulants in ECMO patient in the 
background section. Little research has been published to examine the benefit of TEG in ECMO 
patients, but it’s comprehensive method to examine a comprehensive mapping of the clotting 
system can better direct care.  
Phase three is a comparative evaluation and decision making (Stetler, 2010). For this 
project, feasibility of the application of this knowledge and its qualifying factors are examined. 
The need according to the study question is for an improved method of evaluating bleeding and 
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thrombotic events in ECMO patients. By comparing the practice methods of other institutions in 
the literature, the decision was made to examine the use of TEG and educating nurses and 
ECMO specialists in its applicability.  
Phase four is where this project becomes actualized. This phase applies instrumental, 
conceptual, and symbolic knowledge in a formal method of application (Stetler, 2010). 
Translation of the critiques of the literature and its application to a TEG education module is 
made to develop and implement a continuing education module to determine if staff are then 
more comfortable and more likely to utilize the TEG technology in managing anticoagulants in 
ECMO patients. This application uses multiple strategies to evaluate, such as change agents to 
provide leadership, interactive education, and follow up education (Stetler, 2010). Passive 
education is not considered efficient, there needs to be more to influence change (Stetler, 2010). 
Phase five is evaluation, which can happen at the different types of levels of knowledge 
described previously (Stetler, 2010). The questions to ask in evaluation of this education module 
are as follows: Has this educational module changed the conceptual knowledge at the individual 
level? Has implementation of this knowledge made an instrumental change, by influencing 
practice or policy for this hospital unit? If successful, can symbolic change be made by 
disseminating the findings and influencing the practice on a wider arena? The Stetler Model 
utilizes current research, synthesize of that research in application to an identified need and 
paves a path to implementation and evaluation all the way through to dissemination of 
knowledge at the individual level to the global level. 
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Synthesis of Evidence 
The literature is limited regarding utilizing thromboelastography (TEG) in therapies that 
require long term use, such as in ECMO management. A search was conducted in PubMed, the 
terms “thromboelastography” and “anticoagulants” were used with 1047 results. By restricting 
the search down to the last five years and it use in humans, the results narrow down to 205. 
Excluding literatures focused on ages 19 and older left 133 results. The filter of “ECMO” was 
added, and four articles were left. The same search terms were used in CINAHL and there were 
only four results, but each one was specific to an anticoagulant, not in the methods of monitoring 
patient’s response. I then searched “provider education” and “thromboelastography” and there 
were zero results. Similar searches were conducted with other combinations of these terms. 
Another limitation to the literature appeared to focus on how the TEG could assess a 
pathological problem, but not how the use of TEG could inform clinical decision making to 
avoid complications or guide therapy.  
TEG and ECMO have been documented in the literature extensively, however, they have 
been minimally examined together. Fabbro, Winkler, and Levy (2017) discuss the inability of 
current literature to show what specific point of care test is most efficient in preventing both 
bleeding and thrombosis. TEG provides a more comprehensive view than point of care, and 
therefore could lead the way to changing practice. Instead of looking at the available literature in 
terms of all the concepts in use together, the concepts were researched on an individual basis.  
Extracorporeal Membrane Oxygenation (ECMO) 
The literature review confirms that ECMO therapy can increase survival over aggressive 
ventilatory support. The CESAR trial was a benchmark randomized controlled trial that showed 
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the efficacy of ECMO in respiratory patients. The authors, Peek et al. (2009), followed patients 
from 103 hospitals that treated respiratory failure patients and compared the survival rates. 
Patients in the control group were considered for ECMO if traditional ventilator care was 
insufficient, yet in both groups, outcomes and survivals rates were higher than expected. There 
has yet to be a study similar for cardiac failure and ECMO patient to this authors knowledge.  
One aspect of ECMO and coagulopathies that is important to evaluate is the circuit. As 
previously discussed, the inside of the circuit is an artificial surface that can cause an 
inflammatory response and effect the coagulation profile. Different programs use different 
machines. Malfertheiner et al. (2016) conducted an observational study to determine if there 
were different responses for the CardioHelp, Dideco ECC, and the Deltastream systems. 
Coagulation, inflammatory markers, and hemolysis was found in all the patient, and there was no 
variance between the different circuits. 
Thromboelastography (TEG) 
Only one study was found that directly examined the effect and feasibility of using TEG 
compared to aPTT in managing anticoagulation in ECMO patients. Panigada et al. (2018) found 
that there were fewer hemorrhagic events, though not significantly, and thrombotic events 
remained the same. Northrop et al. (2015) took a different method and made their 
anticoagulation protocol more comprehensive to incorporate multiple individual laboratory 
values in combination with TEG mapping. Their findings were significant for less bleeding 
events and longer circuit life. Crochemore et al. (2017) examined altered coagulopathy in critical 
care patient by comparing TEG whole blood mapping or what they defined as conventional 
coagulation tests (CCT). CCT include platelet counts, fibrinogen, aPTT, PT, and INR. Patients 
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were routinely given blood products based on an isolated CCT, but their TEG would show a 
normal clotting pattern. While there were limitations to the study, they recommend that 
coagulopathy is better determined using whole blood testing (TEG) versus CCT. Deppe et al. 
(2016) conducted a meta-analysis comparing TEG and standard laboratory tests in cardiac 
surgery patient, a population that has high risks for hemorrhagic and thrombotic events. The 
standard laboratory tests included aPTT, prothrombin, INR, platelet counts, and plasma 
fibrinogen. Deppe et al. (2016) concluded that bleeding and thrombotic events were significantly 
decreased when guided by TEG versus the standard laboratory tests, but mortality and hospital 
stays were not significant. The authors also reiterated the need for more RCT’s due to the lack of 
literature and of higher level of study design. Saini et al. (2016) also examined the disruption in 
the coagulopathy in children when introduced to an ECMO circuit. Data was examined to see if 
bleeding events were better predicted when using TEG compared to standard laboratory tests, but 
they were unable to determine that there was a meaningful difference between the different 
laboratory monitoring methods. 
Anticoagulation Techniques 
The literature is very limited on the anticoagulation techniques. Recommended practice 
includes a bolus dose of heparin intravascularly at the moment of cannulation, including for VV, 
VA, VAV, and ECPR (Lequier, Annich, & Massicotte, 2012). Sklar et al. (2016) conducted a 
systematic review to evaluate the different methods that ECMO centers used for venovenous 
(VV) ECMO. This review is limited to the use of aPTT values as this is what most ECMO 
centers use and is recommended by ELSO. The aPTT values used by different ECMO centers 
varied as well. The authors concluded that there is a need for more research to be conducted to 
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examine the best management of anticoagulation in this patient population. A similar systematic 
review was done for venoarterial (VA) ECMO management. Sy et al. (2017) compared levels of 
ACT and aPTT, along with programs that used a multimodal monitoring method including TEG. 
The results did show fewer adverse effects with a multimodal monitoring method, but it was not 
statistically significant.  
A literature search was conducted to investigate the difference in anticoagulation 
protocols between VV and VA ECMO. No research was found specifically for ECMO, but much 
of the current practice is extrapolated from cardiopulmonary bypass (CPB) guidelines developed 
by the American Society of ExtraCorporeal Technology (AmSECT), Society of Thoracic 
Surgeons (STS), and The American Society of Cardiovascular Anesthesiologists (SCA) (Shore-
Lesserson et al., 2018). The most recent guidelines published recommend the use of heparin and 
an ACT threshold >480 seconds during CPB based on limited data (Shore-Lesserson et al., 
2018). Such high doses can cause bleeding when therapy is extended via ECMO, and there is not 
a standardized anticoagulation measurement as there is with CBP (Shore-Lesserson et al., 2018). 
While no literature was found comparing thrombotic events occurring more in VA versus VV 
ECMO, because of the extensive research of anticoagulation in CBP, which is more closely 
related to VA ECMO in terms of circulatory rejection and more cannulas for retrograde flow, it 
can be speculated that risk of thrombi in VA ECMO would be more common. 
METHODS 
The proposed project is based on the understanding that the integration of new 
technology and practices in an already dynamic and high intensity program may be confusing or 
overwhelming for the staff. At the hospital in which the project took place, the ECMO program 
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has relied on isolated laboratory results, such as an aPTT or ACT, to follow anticoagulation 
protocols since the program was established in 2011. With the recognition of the TEG process 
and the sophistication it can provide to the ECMO program, a new protocol is currently being 
developed, integrating aPTT and TEG results. The nurses need improved education to better 
implement these developing protocols. Therefore, the aims of this project are to 1) develop an 
education module on TEG to inform anticoagulation therapies in ECMO; and, 2) solicit opinions 
of ECMO specialists regarding the usefulness of the continuing education module. The module 
will then be edited and disseminated to ECMO specialists at BUMCP, as we as prepared for 
publication. 
Study Design 
This is a descriptive quality improvement project whose overall aim is to improve 
nursing knowledge regarding the use of TEG in ECMO patients through the development of an 
education module using a continuing education format. Feedback from a group of expert and 
intermediate experience in ECMO and TEG reviewed and discussed their perspectives regarding 
the usefulness of the continuing education module. The participants’ feedback was conclusive 
that the module would be helpful for current and future ECMO specialists. 
Setting 
This project took place at Banner University Medical Center (BUMCP) in Phoenix, AZ. 
BUMCP is the largest hospital in the state of Arizona with 733 beds and is a top teaching 
hospital. ECMO patients at BUMCP are typically admitted to either the medical-surgical 
(MSICU) or cardiovascular intensive care units (CVICU). The ECMO program has been in place 
in this facility since 2011. Recently, the ECMO program awarded the Extracorporeal Life 
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Support Organization (ELSO) Award for Excellence in Life Support – Center of Excellence 
Gold level. The number of patients placed on ECMO has fluctuated as the program has grown. In 
2017, there were 39 ECMO patients cannulated. As of July of 2018, they surpassed that statistic.  
Population 
Purposeful and targeted sampling was used to recruit seven participants for Aim 2. First, 
the ECMO program coordinator, two intensivist physicians who manage ECMO patients, and a 
representative of the TEG company that supports the hospital’s use and education of the TEG 
equipment were invited in targeted sampling. Next, all ECMO specialists were asked to 
participate in this project. There are approximately 70 ECMO specialist at BUMCP, all of whom 
are ICU registered nurses. ECMO specialists are a subset of the ICU staff chosen from the more 
experienced and skilled ICU RNs. From the volunteers, three RNs were selected from those with 
who are familiar with working with TEG in the ECMO population. The final expert panel was 
hoped to have a minimum of five to six members, and seven participated. These participants are 
experts in their positions and familiar with the use of ECMO, TEG, and anticoagulation 
strategies. The participants were able to read and speak English. 
Recruitment 
Recruitment consisted of an informational flyer that were placed in the break rooms of 
the MSICU and the CVICU, email sent from the ECMO coordinator to the ECMO team and 
posted in the groups private social media group that communicates information to the team 
(Appendix B). From the group of volunteers, there were five ECMO specialist participants that 
volunteered, three of which returned the feedback form. As noted above and in addition, the PI 
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personally asked the ECMO program coordinator, two intensivist physicians that manage ECMO 
patients, and a representative of the TEG company to participate in the project.  
Data Collection 
Aim 1 
An education module based on a continuing education (CE) model (~1 contact hour) on 
the use of TEG to inform anticoagulation therapies during ECMO. To ensure initial content 
validity, the educational module was developed by the PI, the PI’s advisor, Dr. Leslie Ritter, and 
content expert on the ECMO team.  
Because one desired outcome of this study is to publish the educational module as a CE, 
the module was written to adhere to a professional nursing journal continuing education format. 
Specifically, the CE format used in American Nurse Today, a publication of the American Nurse 
Association, was followed (e.g., https://www.americannursetoday.com/wp-
content/uploads/2015/10/Author-Instructions-2015-16.pdf; https://www.nurse.com/ce-writer-s-
guidelines). 
The data for Aim 1 is the educational module, however a brief description is provided 
here. The goal of the module is to improve the understanding of the application of TEG in 
complex ECMO patients for the ECMO specialist. The objectives of the educational module are 
to: 1) identify what the different values in a TEG tracing mean in relation to coagulopathy; 2) 
understand the role of TEG in addition to conventional laboratory values regarding 
anticoagulation therapy in ECMO patients; and, 3) identify interventions and anticoagulation 
strategies to treat coagulopathies as interpreted by TEG tracing in ECMO.  
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In accordance with the American Nurse Today format, the educational module includes a 
brief introduction followed by content on coagulation physiology, pathophysiology, common 
anticoagulation tests and therapies, and principles of TEG and its application in ECMO patients 
(~3,500 words). Figures and tables are used to augment the narrative as appropriate. A multiple-
choice post-test with review and rationale will follow this content. References and links to 
additional online resources are included. In accordance with the American Nurse Today, the final 
format is in a word (pdf) document.  
Aim 2 
After UA IRB approval and prior to initiation of the study, a flyer was posted for 
members of the ECMO team members in cooperation with the ECMO coordinator that describes 
the purpose and the process of the study. All participants for the focus panel were voluntary. The 
PI personally contacted the ECMO coordinator, two intensivist physicians that manage ECMO 
patients, and a representative of the TEG company. Once the participants (expert focus panel) 
were selected, the education module was given or emailed to each participant. The educational 
module (developed in Aim 1) was reviewed by the participants and returned to the PI with edits 
and feedback provided from a questionnaire sent with the module. The review of the module 
took approximately one hour of their time (one contact hour).  
As mentioned above, the expert group reviewed the module and provided feedback via 
direct meeting with the PI or returning feedback per review questions (Appendix C). The goal of 
the expert group was to determine the usability of the educational module. A total of two hours 
of time (one hour to review materials, one hour in a meeting with the PI), were required of 
participants in Aim 2. 
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Data Analysis 
For Aim 1, the data is in the form of the educational module itself. For Aim 2, the expert 
panel reviewed the educational module before a scheduled meeting or returning individual 
feedback per a provided form (Appendix C). This form had open ended questions focused on the 
strength and weaknesses identified in the information included in the educational module. The PI 
and chair analyzed the critiqued and categorized themes and then described changes to improve 
the content and in preparation for publication.  
Ethical Considerations 
When conducting research and quality improvement projects, ethical principles need to 
be reinforced. Respect for persons, beneficence, and justice are addressed to protect and 
minimize risk to any involved. 
Respect for Persons 
For Aim 1, a case study was fabricated based on possible real events to present a real 
patient scenario and avoid using any real patient information. For Aim 2, to avoid coercion, 
participants (ECMO specialists) were notified of the project by public flyer in the unit and posted 
in the private social media group page. Agreement to attend the review session was considered 
acknowledgment of their willingness to participate in the study. Names were not to be included 
in any data collection, including comments made in open ended questions.  
Beneficence 
There are no risks to the collection of this data identified. At the end of the study, the CE 
module will be available for all ECMO specialists at BUMPC.  
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Justice 
The recruitment consists of the whole ECMO team with the oversight of the BUMCP 
ECMO program coordinator. There were not any conflicts of justice appreciated. This project 
was aimed at provider practice and does not utilize health disparities based on any potential 
targeted population. 
RESULTS 
After an email was sent out and flyers were posted, there were nine volunteers. Due to the 
difficulty or inability for the volunteers to be available for one group, the education module and 
questions in the script were emailed or provided as a hard copy of the module to the participants 
they were not able to attend a live focus group session. UA IRB approved this change in data 
collection (Appendix E). In total, seven participants reviewed the education module and provided 
feedback. Of those, one meeting was held with the PI and two participants, and five participants 
reviewed the module on their own and feedback was submitted by email using the questions 
scripted for the originally planned meeting.  
The participants included the ECMO coordinator and educator (RN) of the ECMO team, 
a hemostasis and TEG clinical consultant (RN) from Haemonetics Corporation, two critical care 
intensivist physicians, one RN ECMO specialist with four or more years of experience on the 
ECMO team, and two RN ECMO specialists with two years of experience. Below is a table with 
their responses (Table 1). 
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TABLE 1. Focus expert opinions. 
Question Intensivist Intensivist TEG 
Representative 
ECMO 
Coordinator 
ECMO 
Specialist 
ECMO 
Specialist 
ECMO 
Specialist 
Comfort with 
interpreting 
TEG 
Expert Expert Expert Expert Intermediate Intermediate Novice 
Vignette 
presents a 
common patient 
situation 
Yes, good 
scenario to make 
you think 
Yes Very Well Excellent Yes, painted a 
clear picture 
Very well Yes, good 
representation 
Does the 
module address 
anticoagulation 
in ECMO? 
Partially, 
anticoagulation in 
an ECMO patient 
is much more 
complicated than 
can be summed 
up here 
Partially, 
anticoagulant needs 
with VA patients are 
relatively increased, 
would need discussion 
on circuit set up 
Yes Yes Yes, it addressed 
anticoagulation 
needs 
Yes, needs 
clearly 
explained, 
reinforced with 
posttest 
questions 
Yes, shows the 
benefit of TEG 
as another tool to 
understand a 
complex 
situation 
Does the 
module improve 
knowledge of 
how TEG 
works? 
Yes, it was clear Case examples with 
interpretations would 
improve the quality of 
the instruction. 
Yes, with small 
edits 
Yes  By simplifying 
each value and 
then looking at 
the TEG as a 
while, it 
provided an 
easy, digestible 
explanation 
Yes, the 
elements of the 
TEG are 
revealed and 
how it is 
applied to the 
patients. 
Shows how the 
TEG is applied 
and why 
physicians ask 
certain questions 
in relation to the 
patient’s 
condition 
How well does 
it tie ECMO and 
TEG together? 
Ties it together 
well 
Clarify that TEG does 
not provide more 
information because 
of coagulopathy, 
coagulopathy is 
already skewed in an 
ECMO patient 
Very well Very well Ties ECMO and 
TEG together 
well, breaks it 
down. 
Appreciate 
discussing the 
basics of ECMO 
and the necessity 
of 
anticoagulation 
Very well, 
connection to 
what the ECMO 
specialist will 
see at the 
bedside is 
especially 
important 
Ties together 
TEG and ECMO 
very well 
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TABLE 1 – Continued  
Question Intensivist Intensivist TEG 
Representative 
ECMO 
Coordinator 
ECMO 
Specialist 
ECMO 
Specialist 
ECMO 
Specialist 
Areas of 
confusion? 
DIC diagnosis 
versus 
coagulopathy, 
DIC is a 
coagulopathy 
Clarify areas of 
interchangeable 
phrases of 
hypercoagulopathy 
and 
hypercoagulability  
K value and α-
angle 
clarification of 
information, the 
use of MAAA in 
platelet mapping 
Clarify TEG 
and TEG with 
heparinase in 
vignette and in 
post test 
questions 
No No No 
Missing 
Information? 
Clarify that these 
concepts are new 
and evolving 
No Add reference to 
ELSO’s “Red 
Book” 
No No No  Comprehensive 
Additional 
suggestions 
Case studies with 
TEG pictures 
Minor grammatical 
errors. Different 
picture example of 
skewed TEG 
waveforms 
No No Add step by step 
interpretation 
examples 
No No 
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TABLE 2. Feedback themes. 
Recommendations  Clarify that the technology and understanding of the interaction with blood and the 
circuit is still evolving.  
 DIC is a type of coagulopathy, may be confusing to differentiate them 
 Correct information on K value, α-angle, and platelet mapping 
 Adding a detailed case study and step by step interpretations of a real TEG 
 Reference to addition of TEG use in ELSO recommendations 
Done well  Vignette provided a clear picture of a common situation in an ECMO patient with 
coagulopathy issues identified by TEG 
 Clear description in how TEG can benefit and be used to assess coagulopathy and 
effectiveness of anticoagulants in ECMO 
 Clear descriptions of the individual values in a TEG 
Content themes that came up multiple times in the participant feedback was to better 
clarify that the technology involved in treating and evaluating this patient population is a moving 
target, and research has not established gold standards or specific guidelines on how to manage 
anticoagulation in this patient population. As there is still difficulty conducting randomized 
control studies given the acuity of this patient population, literature is lacking on best practice, 
but is evolving. The Extracorporeal Life Support Organizations (ELSO) publishes a “Red Book” 
of recommendations that are updated approximately every five years. This is the first year that it 
has included recommendations on the use of TEG in ECMO patients. It was also recommended 
that this information be included in the education. Detailed case studies and visual examples of 
the step by step interpretation of a real TEG was also suggested.  
Positive feedback was also included in the reviews. The vignette was regarded as a good 
example of a common ECMO patient with an underlying coagulopathy that would otherwise not 
have been identified with single value laboratory values (i.e., aPTT or ACT). A table was 
included as a quick reference point for normal ranges of values and possible intervention for 
abnormal results. Descriptions of each value was also made in greater detail and was also found 
to be helpful in understanding the content. 
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DISCUSSION 
ECMO is a quickly evolving therapy which is gaining a lot of attention in recent years. 
ECMO can be associated with severe bleeding disorders and healthcare providers may be 
challenged to understand new assays to assess coagulation, such as thromboelastography (TEG). 
Recognizing the gap in knowledge and identifying the needed education on the use of TEG are 
the first steps in providing optimal care for ECMO patients. The overall purpose of this project 
was to provide education for the ECMO specialist. First, based on current literature, the PI 
developed a continuing education module. The education module was then validated by 
soliciting expert opinions from a diverse group of practitioners (study participants) that work 
closely with the ECMO population. The education module below includes many of the 
recommendations of the expert practitioners. In being consistent with the feedback, it was noted 
that this patient population is complex, and the education provided is to provide a framework for 
practice, as the decisions made in treating these patients with anticoagulation should be based on 
assessment of the individual patient and the provider’s clinical judgement. Being mindful of 
publisher’s expectations for continuing education modules (American Nurse Today, 2016; 
Nurse.com, n.d.), the content changes that were made to the CE module that was initially 
developed were largely based on the input from the TEG representative and were made to clarify 
the information. These changes included clarification of the k value and α-angle and platelet 
mapping. The CE module (Appendix E) contains the following criteria as required by the 
publisher (American Nurse Today, 2016; Nurse.com, n.d.): Abstract of approximately 150-200 
words, one sentence goal statement, core competencies, three objectives, a clinical vignette, 
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introduction, an original, researched, referenced manual of 3,600 words, complete reference list, 
and a 12 multiple-choice question post-test with the correct answers indicated. 
DNP Essentials 
This DNP project was written, developed, and implemented in compliance with the 
University of Arizona’s DNP essential elements. For Essential I, scientific underpinnings for 
practice, this project used research from biophysical, analytical, and organizational sciences 
through development of education that pulls information and practice from multiple 
organizations, including BUMCP, Haemonetics, and protocols from published literature from 
ECMO centers internationally. Complex pathophysiology of the hematological and circulatory 
systems is discussed in detail, along with applied critical care thinking.  
For Essential II, organizational and systems leadership for quality improvement and 
systems thinking, this project achieves this through developing education that is not available in 
a comprehensive manner for clinicians on a complex patient population in effort to better the 
care provided to them. The education was also written with the intention to also be able to be 
beneficial to clinicians outside of BUMCP with room for adjustment as each hospital or ECMO 
center differs in their specific anticoagulation protocols. Also, task force of members from 
multiple disciplines was organized and lead in developing and evaluating the education module.  
Essential III, disseminate findings from evidence-based practice and research to improve 
healthcare outcomes, is met through incorporating this education into the BUMCP ECMO 
education program. This education module was also written with the intention of publication, in 
the form of a continuing education module per ANA and CE Direct guidelines, to disseminate it 
to other hospitals and ECMO centers. 
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This project also meets criteria for DNP Essentials VI, interprofessional collaboration for 
improving patient and population health outcomes. This project relied on the collaboration 
between physicians, nurses, and consultants to develop a cohesive product that has not been 
otherwise developed. It pulls data and practice guidelines from different peer reviewed policies 
and practices, both from BUMCP and other published works to provide clear education on 
management of a complex patient population and new application of TEG technology. 
The last of the DNP essentials met in the development of this project is Essential VIII, 
advanced practice. By creating education for nurses to support their practice and communication 
with providers, this project also creates a framework for future education to grow as the 
technology and application of different tools to evaluation coagulopathy and anticoagulation in 
the ECMO population changes. By designing, developing, and implementing a process of 
evaluation for the education, this project also conducted a comprehensive evaluation of the 
material to support best practice regarding the recommendations for the care of this special 
population.  
Conclusion 
The ECMO patient has many complexities in the management of their care, not the least 
of which involves a coagulopathic state. While researchers and clinicians are actively working to 
develop better ways to monitor and treat the coagulopathy associated with the ECMO patient, 
there is little standardized education available about monitoring anticoagulation for the bedside 
RN ECMO specialists. This DNP project attempts to address this gap in education and support 
the advancement of the RN in furthering their ability to care for this population. By developing a 
continuing education module on the use of TEG in ECMO patients and eliciting the opinions of 
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experts, this project hopes to close this gap in knowledge and disseminate the continuing 
education module to the broader healthcare and critical care community via its publication in a 
peer review journal. Ultimately, it is hoped that this CE module will result in optimal care of the 
ECMO patient. 
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APPENDIX A: 
EVIDENCE APPRAISAL TABLE 
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Data Collection: Date search 
through Medline, EMBASE, and 
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CVA, and thrombotic events. 
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IL-8. 
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examine whether the different 
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hemostasis of the patient’s 
receiving ECMO. While the study 
did not show any significant 
changes, the secondary goal of the 
study was to monitor the changes 
in the blood in response to the 
initiation and discontinuation of 
the therapy. There were significant 
marker changes in coagulation, 
hemolysis, and inflammation once 
introduced to ECMO. Coagulation 
and hemolysis markers stabilized 
once ECMO was discontinued, 
however inflammatory markers 
stayed the same. 
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Daphne, H. C., 
Pietsch, J. B., & 
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(2015). 
Do comprehensive ECMO 
anticoagulation monitoring 
protocols result in fewer 
complications? 
Retrospective 
chart review 
Sample: N=261 CMO runs 
before the initiation of a 
protocol, and 105 ECMO 
runs after the initiation of an 
anticoagulation protocol. 
Setting: Monroe Carell Jr 
Children’s Hospital at 
Vanderbilt 
Data Collection: Complications 
during ECMO runs were compared 
before implementing a revised 
anticoagulant protocol to now 
include anti-factor Xa assay, 
antithrombin levels, and TEG to 
standard ACT, platelet count, 
protime, INR, aPTT, and HCT. 
Data Analysis: Correlational 
statistics were compared before and 
after the implementation of an 
anticoagulant protocol. 
 
Mean use of blood products were 
decreased significantly after 
initiating the new protocol. 
Bleeding at the cannula site was 
significantly decreased (p=0.04) 
and at the surgical incision 
(p=0.02). ECMO circuit life was 
also increased (p=0.02). 
Association of following the 
protocol confirmed the hypothesis 
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Assess the safety and 
feasibility of 
anticoagulation protocols in 
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versus aPTT 
RCT Sample: N=42, all patients 
were on VV ECMO, from 
either ARDS or a bridge to 
lung transplant, over the age 
of 18, and were not 
thrombocytopenic (platelet 
Data Collection: 21 patients were 
randomly placed on the control 
protocol (aPTT), and 21 placed on 
the study protocol (TEG). Baseline 
aPTT and TEG were done in all 42 
patients every morning and then 
Safety outcomes: fewer patients 
had bleeding events in the study 
group (not significant, p=0.21). 
Severity of bleeding was not 
different. Thrombotic events and 
transfusion rates were similar.  
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were not diagnosed with HIT 
Setting: Two Italian ECMO 
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adjusted according to the assigned 
protocol based on an R time of 16-
24 in the TEG group and an aPTT 
ratio of 1.5-2 in the control group. 
Data Analysis: Safety was assessed 
by the amount of hemorrhagic or 
thrombotic events and required 
blood transfusions. Feasibility was 
assessed by how many dose 
adjustments were needed, number 
of results within targeted range, and 
“violations” of protocols, 
interruptions regarding patient 
safety or delays in lab results. 
 
Feasibility outcomes: The study 
group required more rate changes 
per the protocols (p=0.01). Lab 
results were more frequently in the 
targeted range for the control 
group versus the study group 
(p<0.001).  
Peek, G. J., 
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Wilson, A., Allen, 
E., Thalanany, M. 
M., … & 
Elbourne, D. 
(2009). 
ECMO will increase the 
survival without severe 
disability by 6 months 
compared to traditional 
ventilatory support. 
RCT Sample: 103 Hospitals, 
including the main ECMO 
center at Glenfield Hospital, 
92 conventional treatment 
centers and 11 referral 
hospitals. Patients were 
intubated, ages 18-65, 
Murray score of >3.0, 
uncompensated hypercapnia 
with pH<7.20 despite 
treatment. N=180 
Setting: Glenfield Hospital, 
Leicester, United Kingdom 
Data Collection: Patients were 
randomly placed in either group. 
Those that received ECMO were 
transported to Glenfield Hospital. 
Those that received conventional 
ventilator support were advised to 
use a low-pressure and low-volume 
strategy. Death or severe disability 
was then tracked six months post 
treatment to assess quality of life, 
respiratory symptoms, cognitive 
psychological state, and lung 
function. 
Data Analysis: Treatment groups 
were compared statistically  
 
Only a fifth of patients screened 
tolerated conventional treatment, 
and four fifths of the patients 
needed to ECMO treatment. 
Survival to six months was greater 
in the ECMO group. While 
patients that received conventional 
treatment had better outcomes than 
hypothesized, the ECMO group 
had better outcomes.  
Saini, A., Hartman, 
M. E., Gage, B. F., 
Said, A., Gazit, A. 
Z., & Eghyesady, 
P. (2016). 
Assess the incidence of 
platelet dysfunction via 
TEG with children on 
ECMO. 
Retrospective 
chart review 
Sample: All patients <18 
years of age placed on 
ECMO that had TEG platelet 
mapping performed during 
their run. 
Setting: St. Louis Children’s 
Hospital neonatal ICU, 
cardiac ICU, and pediatric 
ICU between 9/2011 to 
Data Collection: Demographics, 
duration of ECMO run, hemostasis 
data (ACT, prothrombin, aPTT, 
platelet counts, fibrinogen, 
antithrombin activity, TEG platelet 
mapping, blood products transfused, 
heparin dose, and other medications 
that can affect platelet activity. 
Data Analysis: Statistical analysis 
Severe bleeding events related to 
platelet dysfunction occur often in 
patients on ECMO. The study was 
not able to predict bleeding events 
by using TEG platelets mapping 
due to the size of the study. 
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12/2012. examined the qualitative platelet 
dysfunction by determining 
frequency of ADP- or AA- 
mediated platelet dysfunction. 
 
Sklar, M. C., Sy, 
E., Lequier, L., 
Fan, E., & Kanji, 
H. D. (2016). 
Evaluate anticoagulation 
techniques in VV ECMO 
patients 
Systematic 
Review 
Sample: Articles were 
analyzed from 1977 to 2015 
to examine major bleeding 
events, thrombotic events, 
and in-hospital mortality. 
Setting: N/A 
 
Data Collection: 18 studies were 
analyzed (N=646) 
Data Analysis: Studies were 
compared among those that targeted 
a specific aPTT range, those with 
aPTT >60 seconds, and targeted 
aPTT <60 seconds  
 
The published literature is very 
limited on scope and consistency. 
This systematic review supports 
the concept that there is a need for 
more research and RCT’s on the 
methods of anticoagulants in VV 
ECMO. 
Sy, E., Sklar, M. 
C., Lequier, L., 
Fan, E., & Kanji, 
H. D. (2017). 
Compare anticoagulation 
practices and prevalence of 
bleeding and thrombotic 
events in VA ECMO. 
Systematic 
review and 
meta-analysis 
Sample: 26 studies with 
n=1496 patients were 
analyzed from 1977 to 
September 27, 2016. 
Setting: N/A 
 
Data Collection: Search of multiple 
electronic databases including 
Medline, PubMed, PubMed Central, 
EMBASE, Current Nursing and 
Allied Health Literature, and 
Cochrane Central Register of 
Controlled Trials. 
Data Analysis: Descriptive 
statistics were used to analyze 
frequencies of major bleeding, 
thrombotic events and estimates of 
mortality rate based on the type of 
multimodal methods of monitoring 
anticoagulants.  
Bleeding events occurred in 13% 
of the patients when lower ACT 
(180 seconds) was used, compared 
to 28% with those using ACT >180 
seconds, 50% in patients 
monitored with aPTT, and 24% of 
patients using mixed methods. 
Thrombotic events occurred in 
12% in patient monitored with 
ACT<180 seconds, 9% in patients 
monitored with ACT >180 
seconds, 3% of patients monitored 
with aPTT, and 6% in patients with 
mixed monitoring methods. The 
authors conclusion is that there is 
not enough data to support one 
method over another and further 
investigation is warranted.  
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APPENDIX B: 
RECRUITMENT FLYER 
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ECMO TEAM 
 
Needed: team members that are well versed in TEG interpretation to 
review a continuing education module for the new and future ECMO 
specialist 
Your opinions will also be included in my doctoral project (no names) 
 
If you would like to be part of this exciting education opportunity, please 
responds/contact me at 
Amy.Moore@bannerhealth.com 
 
Requirements: 
Read the CE (1 hour) 
Meeting with me and others to discuss your feedback (about 2 hours) 
Maybe learn something new 
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APPENDIX C: 
RECRUITMENT EMAIL FROM ECMO COORDINATOR 
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ECMO team members, 
 
You are invited to participate as a volunteer to give feedback on one of our team member’s 
doctoral project. Amy Moore has been working on developing a continuing education module to 
help better inform our team members and future members on how we are applying TEG results 
in helping inform the anticoagulation management of our patients. If you are interested, she will 
email you the module in advance and then will schedule a meeting with 5-6 TEG experts to 
evaluate the effectiveness of the module and gather any additional feedback you have. It will 
take about an hour to read, and she asks that you be willing to participate in a meeting for about 
2 hours. Please let me know who would be interested in helping to contribute to this educational 
opportunity. 
 
Thank you, 
 
Stacy Gerle, RN 
 
BUMCP ECMO Coordinator and Educator 
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APPENDIX D: 
FOCUS GROUP SCRIPT 
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Focus Group Questions 
 
 
1. How comfortable are you with interpreting TEG’s with the ECMO patients? 
2. How well did you think the vignette in CE module served as an example to how TEG can 
alter treatment in ECMO patients? 
 
3. Did the module address anticoagulation needs in ECMO? 
4. How did the TEG information improve knowledge of how TEG’s work? 
5. How well does the education tie ECMO and TEG interpretation together? 
6. Are there areas that are unclear or confusing? 
7. Was there any information that was lacking or missing? 
8. Is there anything else anyone would like to add or suggest? 
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APPENDIX E: 
ECMO CONTINUING EDUCATION MODULE 
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Thromboelastography (TEG) and Its Role in Interpreting Anticoagulation in 
Extracorporeal Membrane Oxygenation (ECMO) 
 
Goal: The goal of this module is to improve the understanding of the application of TEG in a 
complex ECMO patient for ECMO specialist. 
Core Competencies:  
1. Better practices regarding the care of ECMO patients. 
2. Understanding the role of the nurse in managing anticoagulation in the ECMO patient. 
3. Improving communication between nursing and physicians.  
Objectives: 
1. Identify what the different values in a TEG tracing mean in relation to coagulopathy. 
2. Understand the role of TEG in addition to conventional laboratory tests regarding 
anticoagulation therapy in ECMO patients. 
3. Identify interventions to treat coagulopathies as diagnosed by interpreting by TEG 
tracings. 
Clinical Vignette 
Mrs. Day has been on venovenous (VV) ECMO for 2 days from pneumonia that had progressed 
to severe acute respiratory distress syndrome (ARDS). Her blood pressure has been decreasing, 
she has a low-grade fever requiring you to cool the circuit, and she is requiring more vasopressor 
support. There is increased bleeding at the cannula site and dressing changes are needed every 
few hours. She is on a heparin drip titrated to aPTT between 65-80 seconds and has blood drawn 
for TEG analysis every 12 hours. Her most recent lactic acid is 5.2 mmol/L, up from 1.8 mmol/L 
yesterday. This morning her TEG with heparinase values were: R time 4.5 seconds, MA75 mm, 
and LY30 32%. The most recent aPTT is 75. Standard TEG values were: R time 12, MA 80 mm, 
and LY30 28%. 
Question 1- Which of the above out of range value is concerning? 
A. R 
B. MA 
C. LY30 
D. All of the above 
Question 2- What disease process do you suspect? 
A. Cardiogenic shock 
B. Sepsis 
C. Hypercarbic respiratory failure 
D. ECMO circuit failure 
Question 3- What coagulopathy do you suspect is occurring? 
A. Nothing, this is normal 
B. Secondary fibrinolysis 
C. Hypercoagulable 
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D. Primary fibrinolysis 
Question 4- What are the proper interventions for the diagnosis you made in Question 3? 
A. Notify the provider for change in laboratory values 
B. Increase the rate of the heparin per your hospital protocol 
C. Hold the heparin and prepare for possible blood transfusion 
D. Continue the current plan of care 
 
Abstract 
Coagulopathy occurs when the blood’s ability to control clotting is impaired. Coagulopathy is 
complex, and in ECMO patients, it becomes even more so. Conventional laboratory tests such as 
an activated partial thromboplastin time (aPTT) and activated clotting time (ACT), can identify 
pieces of the coagulopathy puzzle but may not reflect the more complex pathophysiology. With 
the addition of TEG analysis, the ECMO specialist can better understand the ECMO patients’ 
coagulopathy, anticipate complications, and communicate with providers regarding the best plan 
of care. This CE will help the ECMO specialist understand what a normal TEG tracing is, what 
abnormal values to look out for, and how those values pertain to their patient.  
Introduction: Background and Current Research 
ECMO has two different applications in critically ill patients. Venovenous (VV) is for 
pulmonary support in severe lung failure, while venoarterial (VA) is cardiac support for severe 
cardiac failure. ECMO therapy is associated with coagulopathies such as thrombosis and 
bleeding. These disorders can be related to the primary diagnosis itself, as well as from exposure 
the large amount of foreign surface of the ECMO circuit. Because the inner lining of the ECMO 
circuit does not mimic the endothelial lining of the patient’s vasculature, platelet activation and 
adherence to the circuit and activation of clotting factors can occur. The sum of these processes 
leads to a widespread inflammatory response which interferes with the body’s ability to properly 
manage its own coagulation factors and, if left untreated, thrombosis can occur. To prevent 
thrombosis, ECMO patients are treated with anticoagulants. Paradoxically, because of complex 
interactions among inflammatory processes and anticoagulant treatment of inflammatory 
reactions, abnormal bleeding can also occur in these patients. Understanding coagulopathy in the 
ECMO is evolving and those in the medical community are still trying to better understand the 
interaction with the circuit, as well as the tools available to assess it. 
Current research and common practice support the use of activated partial thromboplastin time 
aPTT and activated clotting time (ACT) testing to titrate anticoagulants to prevent thrombosis 
and mitigate bleeding (Bollinger, Zenklusen, & Tanaka, 2016). APTT is a blood test that 
measures clotting factors in the intrinsic system, including XII, XI, VIII, and IX. ACT is used 
while patients are receiving unfractionated heparin, also measuring the factors of the intrinsic 
clotting system, to the start time of clot formation. These two tests measure the time to clot 
formation and are useful in monitoring anticoagulation, but do not provide a comprehensive 
assessment of the individual patients’ coagulation profile (Bollinger, Zenklusen, & Tanaka, 
   
49 
2016). Because ECMO increases the complexity of coagulopathies, the use of additional tests 
such as TEG may be warranted (Bollinger, Zenklusen, & Tanaka, 2016). 
Thromboelastography 
TEG is a whole blood viscoelastic blood assay test that measures the lifespan of a clot. It is not a 
substitute for aPTT or ACT but provides additional information of the coagulopathy of an 
ECMO patient, such as information about platelet activity, coagulation, and enzymatic pathways. 
TEG technology was first introduced in 1948 but has gained more popularity in the recent 
decades as computer technology has advanced its ease of use (Whitten & Greilich, 2001). TEG is 
commonly used in trauma, cardiac and liver surgical cases. To date, TEG has not been 
extensively examined in the ECMO patient. Several studies have indicated that when used in 
conjunction with aPTT and other isolated coagulation tests, fewer significant bleeding and 
thrombotic events occur (Panigada et al., 2018). These studies provide evidence that the use of 
TEG could potentially benefit ECMO patients and as its use in this population increases, ECMO 
specialists will require specific knowledge of TEG testing. The Extracorporeal Life Support 
Organization (ELSO) has recently added recommendations for the use of TEG in ECMO to their 
“Red Book”, which is a benchmark reference for ECMO programs internationally. This 
guideline reference is updated along with the latest advances in research. 
 
Figure 1. Normal TEG tracing. (Maryland Critical Care Project, n.d.).  
TEG provides information on both the coagulation and the fibrinolysis timeline, as seen in 
Figure 1. Whole blood is placed in the analyzer and activated via the intrinsic pathway and 
heated to 37 degrees. The sample is then rotated to imitate venous blood flow. A stationary pin is 
placed in the sample, and as a clot is formed on the pin, the analyzer maps the development, 
strength, and lysis of the clot. Because whole blood is used for TEG, the contributions of fibrin, 
platelets and clotting factors can be measured. The individual TEG values are described below. 
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 The R time is the reaction time and measures initial fibrin (clot) formation. In a normal patient, 
this is 5 to 10 minutes. In an anticoagulated ECMO patient, you would expect R time to be 
longer. This is the only value in a TEG profile that would be considered a “normal” abnormal 
value. A shortened R time might alert you to a hypercoagulable state. This value is similar in 
concept to an ACT. 
The K value, or kinetic value, is the time the clot takes to reach a specified strength and is 
measured on the TEG tracing from the end of the R time and when the tracing reaches 20 mm in 
height. This value reflects fibrin-platelet mesh formation. A prolonged K value would suggest 
insufficient fibrinogen function. The K value is derived from about eighty percent fibrinogen and 
twenty percent platelet activity.  
The angle, represented as α on the TEG tracing, is the angle calculated from the split point to the 
tangent where the k value is achieved. This is a result of fibrin and platelet aggregation 
(fibrinogen function). The angle should fall between 45 and 55 degrees. If the angle is less than 
45, then there are likely poor function of fibrinogen and factor VIII. If the angle is greater than 
45, no intervention is typically done. 
Maximum amplitude (MA) represents the maximum strength of the clot. This value is 
calculated from when the clot is formed and starts to level off to when it reaches its maximum 
amplitude on the tracing. Normal range is 50-60 mm. This value measures about eighty percent 
platelets and twenty percent fibrinogen. A high MA represents a prothrombotic state with 
hyperactivity of platelets. A low MA results from either low platelet function or low fibrinogen 
levels.  
LY30 is determined when clot lysis starts and is measured by the degradation of the clot over 30 
minutes once MA is achieved by measuring the decreasing amplitude. Normal values are 0-8%. 
Lysis a normal part of the clotting and healing process. However, hyperfibrinolysis can occurs, 
and are classified as primary or secondary. Primary fibrinolysis is rapid clot breakdown resulting 
in increased levels of fibrinogen degradation products (FDP). Secondary fibrinolysis is the 
breakdown of a clot in the setting of systemic hypercoagulopathy, resulting in consumption of 
coagulation factors. It can be caused by a disease process, such as malignancy or infection, 
medication, or other causes. It is often an early sign of DIC (Fields, n.d.). 
A concerning TEG tracing in the ECMO patient is secondary fibrinolysis. Secondary fibrinolysis 
may represent the first stage of DIC and may present before the patient’s symptoms can alert the 
care team to the disorder. Causes that lead to this pathology include severe sepsis, trauma, liver 
transplantation, and cardiopulmonary bypass (Fay, 2017). While DIC is a diagnosis confirmed 
through clinical presentation and laboratory values, secondary fibrinolysis indicates that the 
patient is at high risk for DIC (Leung, 2017).  
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Parameter Normal 
Value 
Clinical Cause Treatment 
High R time 5-10 minutes Clotting factor deficiency Decrease anticoagulation, FFP 
Low R time 5-10 minutes Enzyme 
hypercoagulopathy 
Enzymatic inhibition (Heparin or 
Bivalirudin) 
High K or α-angle 1-3 minutes 
(K) 
Decreased fibrinogen 
function 
Cryoprecipitate 
Low K or α-angle 53-72 degrees 
(𝛼) 
Platelet 
hypercoagulopathy 
No treatment 
High MA 50-70 mm Platelet 
hypercoagulopathy 
Platelet inhibition (Plavix) 
Low MA 50-70 mm Decreased platelet 
function 
Platelet transfusion, Ddavp 
Elevated LY30 0-8% Primary fibrinolysis Consider anti-fibrinolytics 
Low R, Low K, High MA, 
High LY30 
 Secondary fibrinolysis Treat cause 
Consider increasing heparin or 
antithrombin III 
Unexplained bleeding Normal values Dysfunctional Platelets 
Mechanical Bleed 
Platelet mapping 
Consider Ddavp 
Consider Surgery/OR 
Table 1. TEG parameters and interventions.  
Implications for Practice 
A typical TEG tracing for an ECMO patient is similar to how a hemorrhagic tracing would 
appear (see Figure 2), with an extended R time. It appears this way as the anticoagulation is 
doing its job to slow down initial clotting rates. Heparin is a common anticoagulant and when 
running a TEG, it is important to run one with and without heparinase. The heparinase corrects 
the tracing by counteracting the heparin and as a result, other coagulopathies that would have 
been disguised by the heparin are visualized.  
At BUMCP, the anticoagulation protocol usually consists of daily TEG with either an aPTT 
every 2-4 hours, or an ACT hourly. In the case where a patient would have an R time beyond the 
goal, but the aPTT or ACT is within range, the provider will likely decrease the goal of the aPTT 
or ACT to help bring the R time down to reach goal. A general range of goal R time in the 
ECMO patients is two-three times that baseline R time before anticoagulation was started. This 
range is typically 15-25 but can vary from patient to patient. 
In the case of a patient that is bleeding, but has a normal TEG tracing, there are options to 
explore further or treat. This can include desmopressin, mechanical intervention (i.e. surgery), or 
platelet mapping, which will be discussed further later on. Desmopressin helps increase the 
activity of platelets by increasing levels of clotting factors in the plasma, specifically von 
Willebrand factor, factor VIII, and increases the ability of the platelets to adhere and form clots 
(Desborough et al., 2016).  
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Figure 2. Abnormal tracings (source unknown). 
 
Platelet mapping is an additional test that can be done through TEG. To better understand this, 
platelet mapping can be done to determine how effective the platelets are to forming clots or not 
able to (inhibited). Platelet dysfunction can cause unexplained bleeding with a normal or low 
platelet counts. This dysfunction can be genetic or acquired, caused by drugs or disorders. 
Typically, in the ECMO patient platelet dysfunction will be due to their underlying disease 
process and/or interaction with the bypass circuit itself (Kuter, 2019). Drugs that can also affect 
platelet function are NSAIDs, aspirin, adenosine diphosphate (ADP) receptor inhibitors (such as 
Plavix or Brilinta) and nutraceuticals. Disease processes that cause platelet dysfunction include 
systemic lupus erythematosus, myeloma, uremia, and cirrhosis (Kuter, 2019). When in the 
ECMO circuit, the platelet surface can lose glycoprotein lb/IX binding site for von Willebrand 
factor through absorption of the circuit surface, and then fibrinolysis may be activated (Kuter, 
2019). 
Platelet mapping identifies platelet dysfunction by mapping three different tracings, each one 
respectively represents the maximum amplitude (MA) of the active platelets, inhibited platelets, 
and maximum platelet contribution (Dickerson, n.d.). Maximum platelet function is when none 
of the platelets are inhibited and is activated by thrombin in blood sample (MAthrombin). In a 
second channel, a TEG is run with an activator with fibrin, which shows the platelets completely 
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inhibited (MAA). A third and fourth channel are run with an agonist, either arachidonic acid 
(AA) or adenosine diphosphate (ADP), which will show the current activation of the platelets 
(MAAA and MAADP respectively). In a patient on ECMO or another mechanical circulatory 
device, and is on heparin or bivalirudin, the MAADP is more often compared (Dickerson, n.d.). 
Patients that are on antiplatelet medication would show more of a response with a MAAA. The 
ECMO specialist can see the percentage of inhibition shown by the difference between 
MAthrombin and MAADP/MAAA.  
The current software for platelet mapping requires the ECMO specialist to pick each tracing in a 
specific order to create an image to compare the multiple MAs. To do this, after ordering platelet 
mapping, in the software program the ECMO specialist will chose the MAthrombin first, then then 
MAA, and then the channel run with the agonist of choice.  
 
Figure 3. PlateletMapping tracing example (Fields, n.d.). 
Summary 
As a whole blood test, TEG can provide additional information about the coagulopathy of the 
ECMO patient. Because coagulation can be greatly skewed in ECMO patients, a TEG provides 
information beyond what an aPTT and ACT can provide, such as discern between bleeding 
issues related to low fibrinogen or low platelets. A TEG tracing can also alert the care team when 
the patient may be entering more dangerous coagulopathies that an aPTT and ACT will not 
identify, such as DIC and platelet dysfunction. This additional information provided by TEG and 
platelet mapping can help guide more appropriate treatment for this patient population. Another 
benefit is to prevent inappropriate blood product transfusions, such as platelets or plasma, which 
increases the risk of transfusion acquired inflammatory injuries. As practices regarding 
anticoagulation in ECMO patients advance, the role of the ECMO specialist will be vital in 
contributing to improving the management and care for these patients. Every hospital will have 
their specific protocols on anticoagulation, but this module provides a guide to general 
application and concepts regarding TEG in the ECMO patient for the ECMO specialist.  
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Post Test 
Question 1- What abnormal TEG value do you expect to find in an ECMO patient that is 
anticoagulated appropriately and has no other pathology? 
A. Elevated MA 
B. High R time 
C. LY30 <8% 
D. Elevated K 
Answer: B. The goal of anticoagulation in an ECMO patient is to prevent clotting in the 
circulatory system, including the foreign surface of the ECMO circuit. By increasing the R time, 
the time to clot is increased, decreasing unwanted clotting in the circuit. 
Question 2- In secondary fibrinolysis, what disorder are you concerned the ECMO patient could 
be developing? 
A. Thrombocytopenia 
B. Thrombosis 
C. Disseminated intravascular coagulopathy 
D. Anemia 
 
Answer: C. Secondary fibrinolysis on a TEG can show that inappropriate clot lysis is happening 
in the patient’s circulatory system and can alert the healthcare team that that patient is entering a 
dangerous coagulopathy (DIC) before they become symptomatic.  
 
Question 3- Your ECMO patient is bleeding copiously from the cannula and central line sites. 
Their TEG is normal, PTT is within ordered parameters, and platelets are 105,000. What further 
TEG testing could you order? 
A. Fibrinogen level 
B. D dimer 
C. CBC in 2 hours 
D. Platelet mapping 
 
Answer: D. Platelet mapping can help determine if bleeding can be related to dysfunctional 
platelet, particularly when bleeding exceeds the expectations of other laboratory values. 
Question 4- What treatments would be considered in a patient that was in secondary fibrinolysis 
and is actively bleeding from the cannulation site? (Select all that apply). 
A. Increase the anticoagulation medication dose 
B. Hold all anticoagulation and call the physician 
C. Treat the underlying cause 
D. Administer fresh frozen plasma (FFP) and platelets per protocol 
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Answer: A & C. By increasing the anticoagulation, it can restore anticoagulation pathways and 
decrease hypercoagulability and consumption of clotting factors. Always treat the underlying 
cause. 
Question 5- What coagulopathy factor(s) contribute to the MA? 
A. Von Willebrand factor 
B. Platelets and fibrinogen 
C. Fibrin 
D. Factor V 
Answer: B. The MA values is derived from 80% platelet function and 20% fibrinogen function. 
Question 6- What signs or symptoms might you expect to see on a TEG with heparinase with an 
R time of 48, K value of 3.5, and MA of 38? 
A. Increased bleeding around the cannula site and other incision areas 
B. Fibrin forming in the circuit 
C. Increased blood pressure 
D. Chatter in the circuit 
Answer: A. An R time of 48 is too high for the recommended goal in an ECMO patient and the 
anticoagulation dose may be too high. A K value of 3.5 could possibly indicate decreased 
fibrinogen function, and a low MA of 38 could indicate that platelet function may be low as well. 
Treatment for the K value and MA would not be necessary. The R time is the main concern in 
this scenario. 
Question 7- Overnight the patient had increased bleeding around their cannula site, tracheostomy 
site, and has required red blood cell transfusions. This morning your patient’s R time has gone to 
28, from 14 yesterday. Your latest aPTT was 75 from 2 hours ago and your goal aPTT is 60-80. 
What interventions could you expect to occur? 
A. Decrease your heparin rate and recheck a TEG 
B. Pause the heparin drip for one hour and check another aPTT 
C. Decrease your goal aPTT range to 50-60 
D. Give a pack of cryoprecipitate 
Answer: C. The patient’s R time has had a large increase, as well as increased bleeding to the 
point of requiring a transfusion. While the patient’s aPTT is within goal range, their R time is 
increasing out of the goal range. This patient may need a lower aPTT goal to keep the R time 
therapeutic.  
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Question 8- When you are running a platelet mapping, what tracings do you select in order to 
compare? 
A. MAthrombin, MAA, MAAA 
B. MAAA, MAADP, MAA 
C. MAA, MAthrombin, MAADP/MAAA 
D. MAthrombin, MAA, MAAA 
Answer: C. This is the correct order to program the current platelet mapping system when a 
platelet mapping is ordered to compare the different tracings.  
Question 9- What is the ideal R time for an ECMO patient? 
A. 5-10 minutes 
B. 25-35 minutes 
C. 20-28 minutes 
D. 15-25 minutes 
Answer: D. While some hospital policies may differ on this, the goal R time would be 2-3 times 
the patient’s baseline R time. A normal R time is 5-10 minutes, it is estimated a goal R time in an 
ECMO patient on anticoagulation would be 15-25. 
Question 10- In an ECMO patient, what might be a key factor in the formation of clot formation 
and hemostatic changes? (Select all that apply). 
A. Endothelial wall damage 
B. Low doses of anticoagulation medications 
C. Exposure of blood to the inner surface of the ECMO circuit 
D. Anaerobic metabolism 
Answer: All of the above. Endothelial wall damage activates several clotting factors, which 
triggers the clotting cascade. In an ECMO patient, anticoagulation that is at too low of a dose to 
decrease time to clot formation is not effective and the dose will need to be increased. Exposure 
to the inner surface of the ECMO circuit is identified by clotting factors as a foreign surface and 
will activate the clotting cascade as an inflammatory response, similar to endothelial wall 
damage. Anaerobic metabolism can a 
Question 11- TEG is a whole blood test that can measure what in the coagulopathy of an ECMO 
patient? (Select all that apply). 
A. Fibrinogen 
B. Platelet function 
C. Enzymatic factors 
D. Fibrinolysis 
E. Time to initial fibrin formation 
   
57 
Answer: All of the above. Fibrinogen function is identified in K value or α-angle. The MA is 
dependent on platelet count/function. Enzymatic factors are key in the R time value. Fibrinolysis 
is shown in LY30. Time to initial fibrin (clot) formation is shown in the R time value.  
Question 12- What TEG value might tell you that there is decreased fibrinogen function? 
A. Prolonged K value 
B. Prolonged R time 
C. High MA 
D. High α-angle 
Answer: A. The K value is derived from 80% of fibrinogen function and 20% of platelet 
function. When the K value is prolonged, there is decreased fibrinogen function, decreasing the 
time is takes for the clot to reach 20 mm on the TEG tracing. 
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APPENDIX F: 
THE UNIVERSITY OF ARIZONA INSTITUTIONAL REVIEW BOARD (IRB) APPROVAL 
LETTER 
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